Amgen Inc. (NASDAQ:AMGN) Shares Sold by APG Asset Management US Inc.

APG Asset Management US Inc. trimmed its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,104 shares of the medical research company's stock after selling 1,344 shares during the period. APG Asset Management US Inc.'s holdings in Amgen were worth $2,894,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Centricity Wealth Management LLC purchased a new position in Amgen in the 4th quarter worth $25,000. Ritter Daniher Financial Advisory LLC DE boosted its holdings in Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after purchasing an additional 51 shares in the last quarter. Synergy Investment Management LLC acquired a new stake in shares of Amgen in the 4th quarter valued at about $34,000. Atala Financial Inc acquired a new stake in Amgen during the 4th quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC acquired a new position in Amgen during the 4th quarter worth approximately $36,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Up 1.3 %

AMGN traded up $3.63 during trading on Monday, hitting $289.61. 658,319 shares of the company's stock traded hands, compared to its average volume of 2,771,444. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The stock has a market capitalization of $155.71 billion, a price-to-earnings ratio of 38.36, a PEG ratio of 2.63 and a beta of 0.59. The company's 50 day simple moving average is $304.33 and its two-hundred day simple moving average is $295.11.

Remove Ads

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.29%. Amgen's dividend payout ratio is currently 126.09%.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the company's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company's stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 over the last quarter. 0.69% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AMGN. Johnson Rice set a $294.00 price objective on Amgen in a research report on Wednesday, March 5th. StockNews.com raised Amgen from a "buy" rating to a "strong-buy" rating in a report on Wednesday, April 9th. Morgan Stanley upped their price target on shares of Amgen from $328.00 to $330.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 9th. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Finally, UBS Group reiterated a "hold" rating on shares of Amgen in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Amgen presently has an average rating of "Moderate Buy" and an average price target of $315.22.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.